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ABSTRACT 
 
We have developed and validated a consolidated bead-based genotyping platform, the Bioplex suspension array for 
simultaneous detection of multiple single nucleotide polymorphisms (SNPs) of the ATP-binding cassette transporters. 
Genetic polymorphisms have been known to influence therapeutic response and risk of disease pathologies. Genetic 
screening for therapeutic and diagnostic applications thus holds great promise in clinical management. The allele-
specific primer extension (ASPE) reaction was used to assay 22 multiplexed SNPs for eight subjects. Comparison of the 
microsphere-based ASPE assay results to sequencing results showed complete concordance in genotype assignments. 
The Bioplex suspension array thus proves to be a reliable, cost-effective and high-throughput technological platform 
for genotyping. It can be easily adapted to customized SNP panels for specific applications involving large-scale 
mutation screening of clinically relevant markers. 
 
 
INTRODUCTION 
 
The advances in biomedical science have led to the 
discovery of genes that may influence therapeutic 
outcome and disease susceptibility. Inter-individual 
variability in drug response can often be attributed to 
genetic polymorphisms in genes encoding drug 
metabolizing enzymes, transporters, ion channels and 
drug target receptors (1-4). Genetic screening for 
therapeutic and diagnostic applications thus holds great 
promise though poorly realized at the present moment, 
owing largely to technological limitations. The factors 
that hinder pharmacogenetic testing and molecular 
diagnosis include the laborious and time-consuming 
nature of genotyping, the fidelity of the genotyping 
results, as well as the cost incurred by the test (5). 
Therefore, there is a need to develop a reliable, cost-
effective and high-throughput technological platform for 
genotyping markers involved in the aetiology of variable 
response to drug therapy or disease pathologies. The 
Bioplex suspension array is a potential candidate for the 
development of such a genotyping tool.  
 
The Luminex microbead system has recently been used 
to define single nucleotide polymorphisms (SNPs) of 
human leukocyte antigens (6, 7), minor 
histocompatibility antigens (8), drug metabolizing genes 
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(9, 10), disease genes (11-14), or detect microorganisms 
(15-18). Despite this, the use of the bead technology as a 
genotyping tool is currently still pretty much in infancy. 
Luminex/BioRad offers 100 distinct sets of color-coded 
tiny beads, called microspheres. The polystyrene beads 
are internally-dyed with differing ratios of two spectrally 
distinct fluorophores. The xMAP technology is a 
simultaneous multiplex bioassay using a rapid flow 
cytometer that permits detection of multiple analyses 
bound to the microbeads in solution of a single tube (19, 
20). We describe a genotyping assay that combines an 
allele-specific primer extension (ASPE) with the Bioplex 
suspension array. The assay relies on the sequence-
specific primer extension of two allele-specific capture 
oligonucleotide probes that differ at the last base of the 
3’-end nucleotide defining the alleles. A tag sequence at 
the 5’-end of the capture probe allows the resulting 
enzymatic ASPE product to be captured by its 
complementary sequence (Anti-tags) which has been 
coupled to a specific fluorescent microsphere (Fig. 1).  
 
 
Fig. 1: Schematic diagram of ASPE reaction. 
 
This study attempts to exploit the bead-based 
technological platform to rapidly screen for a basket of 
genetic markers that may impact on drug response. We 
have thus developed and validated a multiplex 
genotyping platform using the Bioplex suspension array 
for detecting a panel of ATP binding cassette (ABC) drug 
transporter polymorphisms. Here, we demonstrate the 
ability of the Bioplex suspension array to simultaneously 
genotype 22 SNPs in a single reaction (Table 1), with 
minimal cross-reactivity. This report provides detailed 
information including primer sequences, anti-
tag/microsphere combinations and experimental 
conditions, hence enabling easy adaptation of the assay 
to customized SNP panels. This thus represents an 
important milestone in the development of genotyping 
technologies and a major step forward in ushering the 
realization of personalized medicine, as well as the use of 
molecular diagnosis in clinical management. 
 
MATERIALS AND METHODS 
 
Oligonucleotides 
 
All oligonucleotides, unless otherwise stated, were 
synthesized by Research Biolabs, Singapore. The PCR 
primers used for generating the various fragments 
encompassing the polymorphism sites (Table 2) were 
unmodified and purified  by standard desalting 
procedures. A 24-mer universal tag sequence was 
incorporated at the 5’-end of each ASPE sequence. The 
ASPE sequences (18-24mer) were designed to be 
matched for melting temperature at 51-56°C. The tag 
sequences were designed using the web-based ‘Tag-IT’ 
Oligo Design software (Tm Bioscience Corporation, 
Toronto, Ontario, Canada). The TAG-ASPE primers were 
unmodified and HPLC-purified (Table 3). The 
complementary oligos (Anti-tags) were amino (NH2)-
modified at 5’-end for covalent attachment to 
carboxylated microspheres and separated from the anti-
tag sequences (Table 4) by a 6-carbon spacer to minimize 
potential interactions with the micropsheres. Anti-tags 
were purified by standard desalting procedures and 
obtained from Sigma-Proligo, Singapore. 
 
Reagents 
 
HotStar Taq 2X Master Mix was obtained from Qiagen. 
Platinum GenoTYPE Tsp  DNA polymerase, individual 
deoxyribonucleoside triphosphates,  and biotin-dCTP 
were purchased from Invitrogen Corporation.  Shrimp 
Alkaline Phosphatase (SAP) was obtained from 
Promega, Madison, USA and Exonuclease I from New 
England Biolabs, Beverly, MA, USA. Bioplex coupling 
beads, sheath fluid, and calibration and validation kits 
were purchased from Bio-Rad Laboratories, Life Science 
Research Group, Hercules, CA. The cross-linker 1-ethyl-
3-(3-dimethylaminopropyl)  carbodiimide hydrochloride 
(EDC) was obtained from Pierce, Rockford, IL.  The 
oligonucleotide coupling and hybridization reagents: 
2[N-Morpholino] ethanesulfonic acid (MES) and Tris-
EDTA buffer were purchased from Sigma Aldrich, NaCl 
from Merck, 10% sodium dodecyl sulfate (SDS) and Tris 
 
Koo et al. - Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array 
www.biologicalprocedures.com     
 
29
from 1st BASE Laboratories Sdn. Bhd, Malaysia, Triton 
X-100 from BioRad, and Tween 20 from USB, Cleveland, 
OH. The platinum grade streptavidin-conjugated 
phycoerythrin  (1 g/L) was obtained from Molecular 
Probes, Eugene, OR, USA. 
 
DNA samples 
 
Whole blood (10 mL) was collected from normal, healthy 
individuals, aged 18 to 40 years old from a previous 
study. All volunteer subjects were recruited in 
accordance with local regulatory and institutional ethics 
requirements (Institutional Review Board, National 
University Hospital, Singapore) and written informed 
consent. Genomic DNA was isolated from whole blood 
using standard desalting methods. DNA samples were 
quantified  spectrophotometrically by measuring 
absorbance at 260 nm, diluted to 5 ng/µL, and stored at 
4°C.  
 
Genotyping by DNA sequencing 
 
A total of eight random samples were subjected to DNA 
sequencing to obtain the genotypic profile of all 22 ABC 
SNPs in each individual. These include both reported 
and novel SNPs residing in potentially functional regions 
of the drug transporters (21-23). For all samples used in 
the study, genotyping results obtained with the Bioplex 
assay were compared with those obtained with dideoxy 
dye-terminator sequencing chemistry. For each of the 22 
SNPs, bidirectional (forward and reverse) sequencing 
was performed using the PCR primers shown in Table 2. 
DNA sequencing reactions were performed using 
BigDye Terminator 3.1 Cycle Sequencing Kit and 
analyzed on the automated ABI Prism Model 3100 Avant 
Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA). 
 
Multiplex PCR (4 panels) 
 
Multiplex PCR refers to the generation of multiple PCR 
products in a single reaction. Four separate multiplex 
PCR panels were required to generate all the fragments 
containing the 22 SNPs. The primer pairs were designed 
such that the SNP lies towards the centre of the PCR 
fragment. The PCR mixtures contained Qiagen Hotstar 
Taq 1X Master Mix, varying concentrations of primers 
(Table 2) and 4 ng of genomic DNA in a final volume of 
20 µL. Following an initial pre-denaturation step at 95°C 
for 15 min, the reactions were cycled 35 times through 
denaturation at 94°C for 1 min, variable annealing 
temperatures (Table 2) for 1 min and extension at 72°C 
for 1 min. The reactions were terminated by an 
additional extension step at 72°C for 10 min. The 
amplification reactions were performed on the Peltier 
Thermal Cycler (DNA Engine Dyad; MJ Research Inc, 
Waltham, MA, USA). The samples were kept at 4°C until 
use. The PCR products were subjected to 1.6% agarose 
gel electrophoresis to verify successful amplification of 
the desired fragments. 
 
Allele-specific primer extension 
 
Prior to ASPE reaction, 10 µL of each PCR product was 
treated with 2 U of Exonuclease I and 1 U of SAP by 
incubating at 37°C for 15 min, followed by enzyme 
deactivation at 80°C for 20 min. SAP inactivates any 
remaining nucleotides  (particularly dCTP) to allow 
efficient incorporation of biotin-dCTP during the primer 
extension reaction and Exonuclease I degrades any 
remaining PCR primers to avoid interference with the 
tagged ASPE primers during the extension reaction. The 
treated samples were  then added directly to the ASPE 
reaction. 
 
Multiplex ASPE reactions comprised 20 mM Tris-HCl 
(pH 8.4), 50 mM KCl, 1.25 mM MgCl2, 5 µM biotin-dCTP, 
5 µM each of dATP, dGTP, and dTTP, 0.75 U of Platinum 
GenoTYPE  Tsp D N A  p o l y m e r a s e ,  2 5  n M  e a c h  T A G -
ASPE primer and 10 µL of pooled treated PCR product in 
a final volume of 20 µL. The ASPE primer sequences are 
listed in Table 3. The ASPE reactions were incubated at 
96°C for 2 min and then subjected to 35 cycles at 94°C for 
30 s, 55°C for 1 min, and 74°C for 2 min. The reactions 
were then held at 4°C until use. 
 
Microsphere coupling 
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The aminated anti-tags were coupled  to their 
corresponding populations of carboxylated microspheres 
using an EDC chemistry (Table 1). Briefly, 2.5 x 106 
microspheres of each population were resuspended in 25 
µL of 0.1 M MES, pH 4.5, followed by addition of 0.2 
nmole of anti-tag oligos. 2.5 µL of freshly-prepared 10 
g/L EDC solution was  added to each microsphere 
mixture and incubated for 30 min in the dark. A second 
2.5 µL aliquot of freshly prepared EDC solution  was 
added and incubated for an additional 30 min in the     
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dark. Following this, the coupled microspheres were 
washed in 500 µL of 0.2% Tween 20 and then 500 µL of 
0.1% SDS. Finally, the pelleted coupled microspheres 
were resuspended in 50 µL of TE (10 mM Tris, 1 mM 
EDTA), pH 8.0. The coupled microspheres were 
enumerated using a  hemacytometer, and stored at 4°C 
protected from light. 
 
Hybridization and detection 
 
Approximately 2500 microspheres of each of the 44 anti-
tag-bearing microsphere sets (Table 1) were combined in 
2X Tm Hybridization Buffer [0.4 M NaCl, 0.2 M Tris (pH 
8.0), 0.16% Triton X-100]. The microsphere mixture was 
concentrated and resuspended to 100 of each 
microsphere set per µL in 2X Tm Hybridization Buffer. A 
25 µL aliquot of the mixture was added to each well of a 
96-well plate (MJ Research). A 10 µL aliquot of each 
ASPE reaction and 15 µL sterile water were then added 
directly to each well. 25 µL of sterile water was added to 
the background well. The samples were then heated to 
96°C for 90 s, followed by 1 hr incubation at 37°C. After 
this incubation, the samples were washed twice with 1X 
Tm Hybridization  Buffer [0.2 M NaCl, 0.1 M Tris (pH 
8.0), 0.08%  Triton X-100]. The microspheres were then 
resuspended in 120  µL of reporter solution (2 mg/L 
streptavidin-conjugated  phycoerythrin in 1X Tm 
Hybridization Buffer) and incubated for 15 min at 37°C. 
The reactions were transferred to a flat-bottomed 96-well 
plate (Nunc) and 50 µL was analyzed on the Luminex 
xMAP/Bioplex system (Bio-Rad Laboratories, Life 
Science Research Group, Hercules, CA) at ambient 
temperature. For each sample, instrument settings were 
configured to read a minimum of 100 events per bead 
region  with the gate setting being defined before the 
samples were run and maintained throughout the course 
of the study. 
 
Data analysis 
 
For each DNA sample subjected to the Bioplex array 
assay, median fluorescence intensity (MFI) values were 
generated for  each of the 44 microsphere populations 
corresponding to each allele within the assay. For each 
allele of a given sample, the NET MFI was set to be the 
larger of zero and the value obtained by subtracting the 
no-target (water control) MFI values from the respective 
MFI values of the sample. The MFI units for at least one 
allele were required to be at least 10 times the no-target 
MFI for  that allele and magnitude of at least 300. The 
genotype was then determined based on the mutant 
allelic ratio where: 
 
 
 
The mutant allelic ratio is defined as the fraction of the 
total NET MFI signal for a given SNP attributed to the 
presence of the mutant allele. Based on pre-set threshold 
values, the allelic  ratio was used to discriminate wild-
type, mutant, and heterozygous  SNP calls. Threshold 
values were empirically determined for each individual 
SNP. The genotype calling was performed with the aid of 
the Bioplex SNP Manager macro software provided by 
BioRad [http://www.bio-rad.com/snpmanager]. 
 
RESULTS 
 
DNA sequencing 
 
A total of eight random DNA samples were sequenced 
for the genotypic profile of the 22 ABC SNPs as shown in 
Table 5. Of the 22 SNPs, all three possible genotypes i.e. 
homozygous wild-type, heterozygous and homozygous 
mutant were present for 15 of them. Only two genotypes 
(homozygous wild-type or mutant and heterozygous) 
were present for six of the SNPs (rs1128503, rs4148557, 
i1-1679, rs1189437, rs1151471 and rs868853). All the 
screened subjects were homozygous mutant for one SNP 
(rs504348) (Table 5). The presence of all three genotypes 
for the majority (68%) of the SNPs analyzed allows a 
reliable assessment of the accuracy of the Bioplex 
suspension array assay.  
 
Multiplex PCR 
 
Multiplex PCR conditions were established in a series of 
preliminary experiments (data not shown). Multiplex 
PCRs were optimized for annealing temperatures and 
individual primer concentrations. A total of 4 multiplex 
PCR panels were required to generate 21 fragments 
containing 22 SNPs analyzed in this study (Table 2).  
 
Bioplex suspension array 
 
Table 6 shows the raw MFI values of each individual 
sample (assayed in duplicates) and a non-template 
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Fig. 3: Graphical representation of allelic ratio (A) Subject 34 and (B) 
Subject 12. 
background control. The results between the duplicates 
for all readouts were clearly consistent. The genotyping 
assay for the 22 SNPs was highly specific and robust; the 
signal-to-noise ratio (specific MFI/background) ranged 
from >10 to >900 and the MFI units ranged from 
approximately 300 to 25,000. Threshold values were 
empirically determined for  each individual SNP. The 
mutant allelic ratio ranged from <0.01-0.28 for wild-type 
calls, 0.19–0.78 for heterozygous calls, and 0.89–1.00 for 
mutant calls. While the heterozygotes exhibited almost 
equal MFI signals for both alleles for the majority of the 
SNPs, the MFI signal of one allele was higher than the 
other for a few SNPs. This could possibly be explained 
by the reasoning that one allele of a SNP amplified 
disproportionately and obscured the presence of the 
other allele. Nonetheless, with prior validation using 
known control samples, the various genotypes are 
clearly distinguishable. Representative allelic ratio 
scatterplots are shown for two of the SNPs (Fig. 2). 
 
DISCUSSION 
 
This study explores an alternative technological 
platform, the bead-based suspension array assay to 
rapidly screen a panel of genetic variants of the ABC 
transporters, some of which have been previously 
genotyped for various ethnic groups in our laboratory 
using minisequencing (21, 22). We have successfully 
developed and validated a consolidated bead-based 
genotyping platform for simultaneous detection of 22 
SNPs in a single reaction. The results obtained using the 
Bioplex suspension array were unambiguous and in 
complete concordance with sequencing. The use of a 
multiplex PCR approach significantly increased the 
through-put and cost-savings of the assay. The ASPE 
method was chosen over single base chain extension and 
oligonucleotide ligation methods for its ability to read 
both alleles from a given SNP in a single tube (18, 24, 25). 
This study is based on a known technology performed 
on a small sample size. Nonetheless, we believe it is 
adequate for demonstrating the functionality of the assay 
as an initial proof-of-concept phase. A more extensive 
validation study involving large-scale population 
screening may subsequently be considered for 
establishing SNP genotyping panels for diagnostic 
applications. 
 
 
Fig. 2: Representative allelic ratio scatterplots (A) rs1045642 and (B) 
rs562. 
 
Figure 3 depicts the graphical representation of allelic 
ratio for two of the study subjects. All the 352 genotypes 
(22 SNPs x 8 subjects x 2 i.e. duplicates) determined by 
the Bioplex suspension array were 100% concordant with 
results obtained using the sequencing approach. 
 
 
The Bioplex suspension array offers several advantages 
over alternative genotyping methodologies. The use of 
direct sequencing has long been regarded as the “gold 
standard” for the identification of genetic variations and 
determination of the nucleotide arrangement in a DNA 
fragment. However, direct sequencing as a genotyping 
tool is not a commercially viable option due to its high 
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cost and the laborious procedures involved. 
Conventional genotyping methods such as allele-specific 
PCR and restriction fragment length polymorphism have 
been criticized for their poor sensitivity and specificity, 
are labour-intensive and time consuming. The 
sophisticated Affymetrix Genechip microarray, though 
powerful and high-throughput, is very expensive and 
serves more as a fishing expedition than a simple 
genotyping exercise catered for a specific application. 
The microarray is an investigative approach used widely 
for the search of candidate genes associated with a 
disease state. The Bioplex platform, on the other hand, 
serves as a diagnostic tool to complement microarray 
analysis by targeting the set of genes identified from the 
search. A predefined SNP genotyping assay for specific 
applications ensures a standardized format for rapid and 
cost-effective genetic analysis. 
 
The Bioplex platform allows for the simultaneous 
detection of up to 50 SNPs in a single reaction well. At 
present, we have proven it to be a robust, reliable and 
reasonably high-throughput genotyping tool for 
multiplex analysis of 22 SNPs. The current system 
interface allows analysis of 2 x 96 = 192 samples in a 
single day, equivalent to a maximum output of 9,600 
genotype designations. This technology positions itself 
strategically between the conventional genotyping 
techniques and the high-end oligonucleotide arrays. 
Most importantly, its versatility enables the addition of 
n e w  S N P s  o r  r e m o v a l  o f  u n w a n t e d  S N P s  t o  c r e a t e  
customized genotyping panels for the consumer. The 
Bioplex platform allows for all genotyping reactions to 
be completed and maintained in a single multiplex assay 
which enables better quality assurance to be achieved. 
Some other appealing factors of the Bioplex platform 
include its requirement for minimal DNA template, true 
liquid phase kinetics, short running time, ease of data 
analysis and affordability. The disadvantages of the 
platform include its ability to only detect known 
mutations, limited throughput due to the current 
commercially available beads, the need for empirical 
determination of the threshold value for genotype 
designation, and the high start-up cost. 
 
This technology offers a promising genotyping platform 
for developing validated multiplex genotyping kits for 
specific commercial and research applications involving 
large-scale mutation screening. There is rising awareness 
among pharmaceutical companies and clinicians on the 
importance of pharmacogenetics. The growing trend of 
pharmaceutical companies integrating the 
pharmacogenetics programme in clinical trials during 
new drug development is becoming evident. In view of 
the emerging field of pharmacogenetics, it is anticipated 
that there will be a high demand for rapid, reliable and 
economical genotyping services from pharmaceutical 
companies, research institutions, hospitals and clinics.  
 
The protocol that we are presenting will indeed be 
helpful to researchers in the field or to newcomers. This 
report provides the technical information necessary for 
establishing SNP panel testing using the Bioplex 
suspension array. Some relevant areas for this 
application include genes that impact on drug 
disposition/therapeutic response or disease 
susceptibility. These SNP panels can be classified as a 
combination of markers that affect response to a given 
drug e.g. a chemotherapeutic agent, those that confer a 
risk for pathologies for which prophylactic therapies are 
available, or those that can be used to complement 
clinical diagnosis of diseases. The application of this 
strategy in therapeutics and disease association studies 
will eventually lead to routine adoption of the platform 
in clinical molecular diagnostics. 
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TABLES 
 
 
 
Table 1: Coupling of anti-tags to their corresponding Bioplex beads. 
Bead No.  SNP ID 
WT  mt 
ABCB1_rs1128503   24  66 
ABCB1_rs2032582   33  75 
ABCB1_rs1045642   17  61 
ABCC1_rs504348   19  51 
ABCC5_ rs1000002   21  53 
ABCC5_ rs3749438   27  54 
ABCC5_ rs4148557   35  56 
ABCC5_rs562 37  62 
ABCC5_rs1132776   42  64 
ABCC5_i1-1205   43  72 
ABCC5_i1-1679   45  74 
ABCC5_i1-1821   47  77 
ABCC4_rs1479390   6  34 
ABCC4_rs2274405 11  36 
ABCC4_rs1189429 12  38 
ABCC4_rs4148436 13  41 
ABCC4_ rs1189437  14  44 
ABCC4_ rs1151471   18  46 
ABCC4_ rs1059762  20  52 
ABCC4_rs868853 25  55 
ABCC4_rs9524885 26  63 
ABCC4_rs869951 28  65 
 
  
Table 2: PCR primer sequences and amplification conditions. 
Panel A (54°C)  Primer 
concentration 
(µM) 
PCR Product Size 
(bp) 
ABCB1_rs1128503F: TCTTTGTCACTTTATCCAGC  0.08 
ABCB1_rs1128503R: TCTCACCATCCCCTCTGT  0.08 
502 
ABCB1_ rs2032582F: TGCAGGCTATAGGTTCCAGG  0.06  284 
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ABCB1_ rs2032582R: TAGGGAGTAACAAAATAACAC  0.06 
ABCB1_rs1045642F: CTCACAGTAACTTGGCAG  0.14 
ABCB1_rs1045642R: CTTACATTAGGCAGTGAC  0.14 
315 
ABCC1_rs504348F: CAGGATGAAATGAGGGCACAG  0.12 
ABCC1_rs504348R: GAAGCGCCTGGGATCTTTGG  0.12 
155 
Panel B (56°C)    
ABCC5_ rs3749438F: GGGTGAAATGGAACTGACTC  0.03 
ABCC5_ rs3749438R: GGTGCCCAGGAAACAGAG  0.03 
390 
ABCC5_i1-1821/1679F: CAACATATATGAAGTATTTCAGCGG 0.35 
ABCC5_i1-1821/1679R: GAAATATCTTTATGAACTTGGGAG  0.35 
770 
ABCC5_i1-1205F: CAAGAATATGCTGCTTTACG  0.16 
ABCC5_i1-1205R: TAACCCGTTGAGAGTCGTCA 0.16 
859 
ABCC5_rs1132776F: AGCCCAGGGTCATATGAACAGAGA  0.02 
ABCC5_rs1132776R: AGGCAAAAAGTCAACAACAACCAG  0.02 
477 
ABCC5_rs562F: GCAGGTCCCAAAGCCATTCAGG  0.03 
ABCC5_rs562R: ACCGCAGTCGTCGCACAGTCTCT  0.03 
408 
ABCC5_rs1000002F: CTGGCCTGTCCTAGCTGGGTATG  0.05 
ABCC5_rs1000002R: CTCTGCCTCTTCCTCTTTGCTTCC  0.05 
291 
ABCC5_ rs4148557F: GTTGGGGCGGTGAGCAGTTTG  0.04 
ABCC5_ rs4148557R: TTCCCCACACCCTTCATACATAGA  0.04 
316 
Panel C (60°C)    
ABCC4_ rs1189429F: AGTGACAGTTATTGAGGTTTC  0.12 
ABCC4_ rs1189429R: ATCTGCCTCTTTCCACTCC  0.12 
290 
ABCC4_ rs1189437F: ACACCATCTCTACTAAAAATAC  0.20 
ABCC4_ rs1189437R: CAGAGACCACACCAACCAC  0.20 
457 
ABCC4_ rs868853F: CGCCCGACCAATATCTCACTTTT  0.10 
ABCC4_ rs868853R: TCCTACAGCCATTCAACCAGCATA  0.10 
230 
ABCC4_rs869951F: GCCTGCGCCGCTGGATGGA  0.05 
ABCC4_rs869951R: TCGAGTTACCCGGCTTTCTTGAGG  0.05 
393 
ABCC4_ rs4148436F: GGTGTCTGTGTGTGGGGAGT  0.04 
ABCC4_ rs4148436R: TAAGAGTGAACCCTGCCACA  0.04 
482 
ABCC4_ rs1479390F: CACTGCCAGGGCCTCAAAATGTA  0.07 
ABCC4_ rs1479390R: ATGCAGCTGCCAAATGGAAGTCTA  0.07 
620 
ABCC4_ rs1151471F: TGACTCTTGGTTCCTCTATAGC  0.15 
ABCC4_ rs1151471R: AGGACACAATATAACATCTTGC  0.15 
202 
Panel D (56°C)    
ABCC4_ rs1059762F: CCTCTCAGAATAAGGTGTCAC  0.10 
ABCC4_ rs1059762R: CATTAAAACAGAAACAGGACG  0.10 
437 
ABCC4_ rs2274405F: CACAGCCCCATACAGCGTCACT  0.10 
ABCC4_ rs2274405R: TTTTTGTTGTTGTTGCCCAGGATG  0.10 
318 
ABCC4_ rs9524885F: AGGAATGGAGGGAATGAGTT  0.15 
ABCC4_ rs9524885R: CTTGTAGAACGTGATCAAAATG  0.15 
637 
The annealing temperatures of the various multiplex PCR panels are indicated in parentheses. 
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Table 3: TAG-ASPE primer sequences. 
Tagged ABCB1_rs1128503wt: TACATACACTAATAACATACTCAT CTGGTAGATCTTGAAGGGC   
Tagged ABCB1_rs1128503mt: CAATTTACTCATATACATCACTTT CTGGTAGATCTTGAAGGGT   
Tagged ABCB1_ rs2032582wt: ATACTACATCATAATCAAACATCA ATAAGAAAGAACTAGAAGGTG   
Tagged ABCB1_ rs2032582mt: ATCATACATACATACAAATCTACA ATAAGAAAGAACTAGAAGGTT   
Tagged ABCB1_rs1045642wt: CAATTAACTACATACAATACATAC TGGTGTCACAGGAAGAGATC   
Tagged ABCB1_rs1045642mt: CTACAAACAAACAAACATTATCAA TGGTGTCACAGGAAGAGATT   
Tagged ABCC1_rs504348wt: AATCAATCTTCATTCAAATCATCA GGATACTGTCCTTAAACAGC   
Tagged ABCC1_rs504348mt: TCAATCAATTACTTACTCAAATAC GGATACTGTCCTTAAACAGG   
Tagged ABCC4_rs2274405wt: CTACTATACATCTTACTATACTTT ATTTTGCTTGCACTGAAAAAT 
Tagged ABCC4_rs2274405mt: CTATCTATCTAACTATCTATATCA ATTTTGCTTGCACTGAAAAAC 
Tagged ABCC4_rs1189429wt: CTTTCTATCTTTCTACTCAATAAT GGTGATCTCATGCCCTTG 
Tagged ABCC4_rs1189429mt: CTTTTACAATACTTCAATACAATC GGTGATCTCATGCCCTTA 
Tagged ABCC4_ rs1189437wt: TCATTCATATACATACCAATTCAT AGTATTCTTTTCAAAAATACTTG 
Tagged ABCC4_ rs1189437mt: TCAATTACTTCACTTTAATCCTTT AGTATTCTTTTCAAAAATACTTT 
Tagged ABCC4_rs868853wt: CAATTTCATCATTCATTCATTTCA CCATTCAAGGTTATCCTTAC 
Tagged ABCC4_rs868853mt: TTACTTCACTTTCTATTTACAATC CCATTCAAGGTTATCCTTAT 
Tagged ABCC4_rs869951wt: TTCAATCATTCAAATCTCAACTTT TTCTCAGGACCAAACGAC 
Tagged ABCC4_rs869951mt: AAACTAACATCAATACTTACATCA TTCTCAGGACCAAACGAG 
Tagged ABCC4_rs9524885wt: TCATTTACCAATCTTTCTTTATAC TGCTGATGCTGCTAATCCT 
Tagged ABCC4_rs9524885mt: CTATCTTTAAACTACAAATCTAAC TGCTGATGCTGCTAATCCC 
Tagged ABCC4_rs4148436wt: TCATTTCAATCAATCATCAACAAT AGCCCCATCAGTAGCACA 
Tagged ABCC4_rs4148436mt: TCAATTACCTTTTCAATACAATAC AGCCCCATCAGTAGCACG 
Tagged ABCC4_rs1479390wt: TACACTTTCTTTCTTTCTTTCTTT AATTGTTGTGAGTCCACTTG 
Tagged ABCC4_rs1479390mt: TTACCTTTATACCTTTCTTTTTAC AATTGTTGTGAGTCCACTTT 
Tagged ABCC4_rs1151471wt: CAATAAACTATACTTCTTCACTAA AAATTGTAGCTATAAGATGATC 
Tagged ABCC4_rs1151471mt: TCATTTCACAATTCAATTACTCAA AAATTGTAGCTATAAGATGATT 
Tagged ABCC4_rs1059762wt: AATCTTACTACAAATCCTTTCTTT ACATTTTGAATATAGCTATCG 
Tagged ABCC4_rs1059762mt: AATCCTTTTACATTCATTACTTAC ACATTTTGAATATAGCTATCA 
Tagged ABCC5_ rs1000002wt: CTTTTCATCTTTTCATCTTTCAAT TAGCTCTGATGGTTCTCAC   
Tagged ABCC5_ rs1000002mt: TTACTTCACTTTCTATTTACAATC TAGCTCTGATGGTTCTCAT   
Tagged ABCC5_ rs4148557wt: TCATTTACTCAACAATTACAAATC CGGTGAGCAGTTTGAAACA   
Tagged ABCC5_ rs4148557mt: CTTTAATCTCAATCAATACAAATC CGGTGAGCAGTTTGAAACG   
Tagged ABCC5_ rs3749438wt: CTTTTCATCAATAATCTTACCTTT GCACTTGGTATGTTCCCG   
Tagged ABCC5_ rs3749438mt: CTTTAATCCTTTATCACTTTATCA GCACTTGGTATGTTCCCA   
Tagged ABCC5_i1-1821wt: TCAAAATCTCAAATACTCAAATCA ACACCCAATCTCATTCATAA   
Tagged ABCC5_i1-1821mt: AATCTAACAAACTCATCTAAATAC ACACCCAATCTCATTCATAG   
Tagged ABCC5_i1-1679wt: CTAACTAACAATAATCTAACTAAC TGACAAAGTTTTTGAATAATAAA   
Tagged ABCC5_i1-1679mt: TACACTTTAAACTTACTACACTAA TGACAAAGTTTTTGAATAATAAT   
Tagged ABCC5_i1-1205wt: TCATCAATCTTTCAATTTACTTAC ACTTGTCCATCTTTATAACAG   
Tagged ABCC5_i1-1205mt: TCATCAATCAATCTTTTTCACTTT ACTTGTCCATCTTTATAACAA   
Tagged ABCC5_rs1132776wt: CTATCTTCATATTTCACTATAAAC GATGCTCTGGAAGTACCCA   
Tagged ABCC5_rs1132776mt: TCATAATCTCAACAATCTTTCTTT GATGCTCTGGAAGTACCCG   
Tagged ABCC5_rs562wt: TATATACACTTCTCAATAACTAAC GCAACGCTGACCATTCAAT   
Tagged ABCC5_rs562mt: AATCTACACTAACAATTTCATAAC GCAACGCTGACCATTCAAC   
The tag sequences are indicated in italics. 
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Table 4: Anti-tag primer sequences. 
Anti-Tagged ABCB1_rs1128503wt: ATGAGTATGTTATTAGTGTATGTA 
Anti-Tagged ABCB1_rs1128503mt: AAAGTGATGTATATGAGTAAATTG 
Anti-Tagged ABCB1_ rs2032582wt: TGATGTTTGATTATGATGTAGTAT  
Anti-Tagged ABCB1_ rs2032582mt: TGTAGATTTGTATGTATGTATGAT  
Anti-Tagged ABCB1_rs1045642wt: GTATGTATTGTATGTAGTTAATTG  
Anti-Tagged ABCB1_rs1045642mt: TTGATAATGTTTGTTTGTTTGTAG  
Anti-Tagged ABCC1_rs504348wt: TGATGATTTGAATGAAGATTGATT  
Anti-Tagged ABCC1_rs504348mt: GTATTTGAGTAAGTAATTGATTGA  
Anti-Tagged ABCC4_rs2274405wt: AAAGTATAGTAAGATGTATAGTAG  
Anti-Tagged ABCC4_rs2274405mt: TGATATAGATAGTTAGATAGATAG 
Anti-Tagged ABCC4_rs1189429wt: ATTATTGAGTAGAAAGATAGAAAG  
Anti-Tagged ABCC4_rs1189429mt: GATTGTATTGAAGTATTGTAAAAG 
Anti-Tagged ABCC4_ rs1189437wt: ATGAATTGGTATGTATATGAATGA  
Anti-Tagged ABCC4_ rs1189437mt: AAAGGATTAAAGTGAAGTAATTGA 
Anti-Tagged ABCC4_rs868853wt: TGAAATGAATGAATGATGAAATTG 
Anti-Tagged ABCC4_rs868853mt: GATTGTAAATAGAAAGTGAAGTAA 
Anti-Tagged ABCC4_rs869951wt: AAAGTTGAGATTTGAATGATTGAA  
Anti-Tagged ABCC4_rs869951mt: TGATGTAAGTATTGATGTTAGTTT 
Anti-Tagged ABCC4_rs9524885wt: GTATAAAGAAAGATTGGTAAATGA  
Anti-Tagged ABCC4_rs9524885mt: GTTAGATTTGTAGTTTAAAGATAG 
Anti-Tagged ABCC4_rs4148436wt: ATTGTTGATGATTGATTGAAATGA  
Anti-Tagged ABCC4_rs4148436mt: GTATTGTATTGAAAAGGTAATTGA 
Anti-Tagged ABCC4_rs1479390wt: AAAGAAAGAAAGAAAGAAAGTGTA  
Anti-Tagged ABCC4_rs1479390wt: GTAAAAAGAAAGGTATAAAGGTAA 
Anti-Tagged ABCC4_rs1151471wt: TTAGTGAAGAAGTATAGTTTATTG  
Anti-Tagged ABCC4_rs1151471mt: TTGAGTAATTGAATTGTGAAATGA 
Anti-Tagged ABCC4_rs1059762wt: AAAGAAAGGATTTGTAGTAAGATT  
Anti-Tagged ABCC4_rs1059762mt: GTAAGTAATGAATGTAAAAGGATT 
Anti-Tagged ABCC5_ rs1000002wt: ATTGAAAGATGAAAAGATGAAAAG 
Anti-Tagged ABCC5_ rs1000002mt: GATTGTAAATAGAAAGTGAAGTAA 
Anti-Tagged ABCC5_ rs4148557wt: GATTTGTAATTGTTGAGTAAATGA 
Anti-Tagged ABCC5_ rs4148557mt: GATTTGTATTGATTGAGATTAAAG 
Anti-Tagged ABCC5_ rs3749438wt: AAAGGTAAGATTATTGATGAAAAG  
Anti-Tagged ABCC5_ rs3749438mt: TGATAAAGTGATAAAGGATTAAAG 
Anti-Tagged ABCC5_i1-1821wt: TGATTTGAGTATTTGAGATTTTGA  
Anti-Tagged ABCC5_i1-1821mt: GTATTTAGATGAGTTTGTTAGATT 
Anti-Tagged ABCC5_i1-1679wt: GTTAGTTAGATTATTGTTAGTTAG 
Anti-Tagged ABCC5_i1-1679mt: TTAGTGTAGTAAGTTTAAAGTGTA 
Anti-Tagged ABCC5_i1-1205wt: GTAAGTAAATTGAAAGATTGATGA 
Anti-Tagged ABCC5_i1-1205mt: AAAGTGAAAAAGATTGATTGATGA 
Anti-Tagged ABCC5_rs1132776wt: GTTTATAGTGAAATATGAAGATAG  
Anti-Tagged ABCC5_rs1132776mt: AAAGAAAGATTGTTGAGATTATGA 
Anti-Tagged ABCC5_rs562wt: GTTAGTTATTGAGAAGTGTATATA  
Anti-Tagged ABCC5_rs562mt: GTTATGAAATTGTTAGTGTAGATT 
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Table 5: Genotypic profile of each study subject. 
Subject ID  SNP ID 
01 02 34 35 11 12 13 14 
ABCB1_rs1128503   CT TT TT TT CT TT TT CT 
ABCB1_rs2032582   GT  GT  TT  TT  GT  GG  GT  GA 
ABCB1_rs1045642   CT CT TT TT CT CT CC CC 
ABCC1_rs504348    GG GG GG GG GG GG GG GG 
ABCC5_  rs1000002    CC CT CT TT CC CC CC TT 
ABCC5_ rs3749438   GG  GG  AA  GG  GA  AA  AA  GA 
ABCC5_  rs4148557   AG AG GG GG AG GG GG GG 
ABCC5_rs562  TT TC TC CC TT TT TT CC 
ABCC5_rs1132776   AA AG GG GG AG GG GG GG 
ABCC5_i1-1205    GA GG AA GA GA AA AA AA 
ABCC5_i1-1679    AT AA AA AT AA AA AA AT 
ABCC5_i1-1821    AA AA GG AA AA AA AA AG 
ABCC4_rs1479390   GT GT GG TT GG GG GG GG 
ABCC4_rs2274405  CC TC TT TC TT TC CC TC 
ABCC4_rs1189429  AA AA GA AA GA GG GA GA 
ABCC4_rs4148436  AG GG AG AA AG AG AG AG 
ABCC4_  rs1189437 TT TT TT TT GT TT TT TT 
ABCC4_  rs1151471    TT TT TT TT CT TT TT TT 
ABCC4_  rs1059762 AA AA GA GA GG AA AA AA 
ABCC4_rs868853  TT TT CT TT TT CT TT CT 
ABCC4_rs9524885  CC TC TT CC CC TT TC TC 
ABCC4_rs869951  GG CG CC GG GG CG CG CG 
Wild-type is indicated by the 1st nucleotide of the genotype nomenclature 
 
Table 6a: MFI values of each microsphere set corresponding to each allele of ABCB1, ABCC1 and ABCC5. 
 
N: normal, M: mutant, blue: homozygous wild-type, yellow: heterozygous, pink: homozygous mutant 
The SNPs are denoted by the last 3-4 digits of their respective full ID. 
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Table 6b: MFI values of each microsphere set corresponding to each allele of ABCC4. 
 
N: normal, M: mutant, blue: homozygous wild-type, yellow: heterozygous, pink: homozygous mutant  
The SNPs are denoted by the last 3 digits of their respective full ID. 
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PROTOCOLS 
 
Microspheres should be protected from prolonged exposure to light throughout the following procedures.  
 
Microsphere coupling 
 
1.  Bring a fresh aliquot of -20°C, desiccated EDC powder to room temperature. 
2.  Resuspend the amine-substituted oligonucleotide (“probe” or “capture” oligo) to 100 µM in sterile water. 
3.  Resuspend the stock microspheres by vortexing for approximately 20 seconds. 
4.  Transfer 2.5 x 106 of the stock microspheres to a microfuge tube. 
5.  Pellet the stock microspheres by microcentrifugation at 10,000 x g for 3 minutes. 
6.  Remove the supernatant and resuspend the pelleted microspheres in 25 µL of 0.1 M MES, pH 4.5 by vortexing for 
approximately 20 seconds. 
7.  Add 2 µL of the capture oligo (100 µM) to the resuspended microspheres and mix by vortexing. 
8.  Prepare a fresh solution of 10 g/L EDC in sterile water. (Note: Return the EDC powder to desiccant to re-use for the 
second EDC addition.) 
9.  One by one for each reaction, add 2.5 µL of fresh 10 g/L EDC to the microspheres and mix by vortexing. 
10. Incubate for 30 minutes at room temperature in the dark. 
11. Prepare a second fresh solution of 10 g/L EDC in sterile water.  
12. One by one for each reaction, add 2.5 µL of fresh 10 g/L EDC to the microspheres and mix by vortexing. 
13. Incubate for 30 minutes at room temperature in the dark. 
14. Add 500 µL of 0.02% Tween-20 to the coupled microspheres. 
15. Pellet the coupled microspheres by microcentrifugation at 10,000 x g for 3 minutes. 
16. Remove the supernatant and resuspend the coupled microspheres in 500 µL of 0.1% SDS by vortexing. 
17. Pellet the coupled microspheres by microcentrifugation at 10,000 x g for 3 minutes. 
18. Remove the supernatant and resuspend the coupled microspheres in 50 µL of TE, pH 8.0 by vortexing for 
approximately 20 seconds. 
19. Enumerate the coupled microspheres by hemacytometer: 
a)  Dilute the resuspended, coupled microspheres 1:100 in sterile water. 
b)  Mix thoroughly by vortexing. 
c)  Transfer 10 µL to the hemacytometer. 
d)  Count the microspheres within the 4 large corners of the hemacytometer grid. 
e)  Microspheres/µL = (Sum of microspheres in 4 large corners) x 2.5 x 100 (dilution factor). (Note: maximum is 
50,000 microspheres/µL.) 
20. Store coupled microspheres refrigerated at 4°C in the dark. 
 
Hybridisation and detection 
 
1.  Select the appropriate microsphere sets and resuspend by vortexing for approximately 20 seconds. 
2.  Combine 2500 microspheres of each set per reaction. 
3.  Concentrate the microsphere mixture by centrifugation at 10,000 x g for 3 minutes. 
4.  Remove the supernatant and resuspend to 100 of each microsphere set per µL in 2X Tm Hybridization Buffer by 
vortexing for approximately 20 seconds. 
5.  Aliquot 25 µL of the microsphere mixture to each well. 
6.  Add 25 µL of sterile water to each background well. 
7.  Add 10 µL of each ASPE reaction to appropriate wells. (Note: 5 µL is usually sufficient.) 
8.  Adjust the total volume to 50 µL by adding 15 µL of sterile water to each sample well. 
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9.  Cover the plate to prevent evaporation and denature at 96°C for 90 seconds. 
10. Hybridize at 37°C for 1 hour. 
11. Pellet the microspheres by centrifugation at 5000 x g for 3 minutes and remove the supernatant. 
12. Resuspend the pelleted microspheres in 70 µL of 1X Tm Hybridization Buffer. 
13. Pellet the microspheres by centrifugation at 5000 x g for 3 minutes and remove the supernatant. 
14. Repeat steps 11 and 12 for a total of two washes. 
15. Resuspend microspheres in 120 µL of 1X Tm Hybridization Buffer containing 2 mg/L streptavidin-R-
phycoerythrin. 
16. Incubate at 37°C for 15 minutes. 
17. Analyze 50 µL at room temperature on the Luminex xMAP/Bioplex analyzer. 